Search
Returning search results with filters:
Remove filter for
Audience: Healthcare
Remove filter for
Issue: COVID
Remove filter for
Type: Alert
Clear all
Search filters
Type
Audience
Category
Issue
Last updated
Displaying 1 - 1 of 1 items.
Casirivimab and Imdevimab – High Risk of Treatment Failure Due to Circulation of SARS-CoV-2 Omicron Variant
AlertHealth professional risk communication | 2022-01-07